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Evolving evidence on a link 
between the ZMYM3 exceptionally 
long GA‑STR and human cognition
H. Afshar1, S. Khamse1, F. Alizadeh2, A. Delbari1, R. Najafipour3, A. Bozorgmehr4, 
M. Khazaei1, F. Adelirad5, A. Alizadeh6, A. Kowsari7 & M. Ohadi1*
The human X‑linked zinc finger MYM‑type protein 3 (ZMYM3) contains the longest GA‑STR identified 
across protein‑coding gene 5′ UTR sequences, at 32‑repeats. This exceptionally long GA‑STR is located 
at a complex string of GA‑STRs with a human‑specific formula across the complex as follows: (GA)8‑
(GA)4‑(GA)6‑(GA)32 (ZMYM3‑207 ENST00000373998.5). ZMYM3 was previously reported among the 
top three genes involved in the progression of late‑onset Alzheimer’s disease. Here we sequenced the 
ZMYM3 GA‑STR complex in 750 human male subjects, consisting of late‑onset neurocognitive disorder 
(NCD) as a clinical entity (n = 268) and matched controls (n = 482). We detected strict monomorphism 
of the GA‑STR complex, except of the exceptionally long STR, which was architecturally skewed 
in respect of allele distribution between the NCD cases and controls [F (1, 50) = 12.283; p = 0.001]. 
Moreover, extreme alleles of this STR at 17, 20, 42, and 43 repeats were detected in seven NCD 
patients and not in the control group (Mid‑P exact = 0.0003). A number of these alleles overlapped 
with alleles previously found in schizophrenia and bipolar disorder patients. In conclusion, we propose 
selective advantage for the exceptional length of the ZMYM3 GA‑STR in human, and its link to a 
spectrum of diseases in which major cognition impairment is a predominant phenotype.
Abbreviations
AD  Alzheimer’s disease
BPD  Bipolar disorder
NCD  Neurocognitive disorder
SCZ  Schizophrenia
STR  Short tandem repeat
TSS  Transcription start site
UTR  Untranslated region
ZMYM3  Zinc finger MYM-type protein 3
Human-specific characteristics and phenotypes such as late-onset neurocognitive disorder (NCD) (also known 
as dementia) are likely to be the consequence or by-product of human-specific evolutionary events. In agreement 
with the above model, recent emerging evidence indicates that signals of brain evolution in anatomically mod-
ern humans are strongly related to the Alzheimer disease (AD)  pathways1. Remarkably, certain human-specific 
derived alleles protect against post-reproductive cognitive  decline2.
In comparison to single nucleotide substitutions, short tandem repeats (STRs) offer a significantly more 
versatile reservoir of genetic variations that may be necessary for speciation and species-specific  phenotypes3. 
Following a genome-scale analysis of all human protein- coding genes annotated in the GeneCards database, we 
previously reported a catalog of genes containing “exceptionally long” STRs (> 5 repeats) in their core  promoters4,5 
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and the 5′ untranslated region (UTR)6. The emerging comparative and functional analyses of a number of the 
identified STRs support adaptive evolutionary patterns for the expansion of a number of these  STRs3,7, and the 
co-occurrence of alleles at the extreme ends of these STRs with major human cognitive disorders, including 
schizophrenia (SCZ), bipolar disorder (BPD) and late-onset  NCD8–12 .In line with the above findings, recent 
reports indicate that STR length influences expression quantitative trait loci (eQTL)  associations13.
In the category of GA-STRs, the zinc finger MYM-type containing 3 (ZMYM3) gene contains the longest 
annotated 5′ UTR GA-STR at 32-repeats6, which is part of a complex of four consecutive GA-STRs of human-
specific formula across the complex (ZMYM3-207 ENST00000373998.5) (Table 1)8. ZMYM3 is located at Xq13.1, 
and encodes a zinc-finger protein, which is a component of histone deacetylase-containing multiprotein com-
plexes that function through modifying chromatin structure to keep genes  silent14.
ZMYM3 was previously reported among the top three genes involved in the progression of late-onset  AD15. 
Several alternatively spliced transcript variants have been found for this gene, of which the variant containing 
the exon 1 5′UTR is specifically expressed in the  brain16, and spans the GA-STR  complex6. Disruption of this 
GA-STR complex was reported in a X:13 translocation in a case of X-linked mental  retardation17. More recently, 
deleterious mutations in the coding sequence of this gene were reported in conjunction with X-linked intellectual 
disability in a Finish family by X-exome  sequencing18.
Here we sequenced the ZMYM3 GA-STR complex in late-onset neurocognitive disorder (NCD) patients and 
matched controls. This investigation was founded on the following facts: the role of ZMYM3 as one of the top 
three genes involved in the progression of late-onset AD, exceptional length of the STR in human and human-
specificity of the STR complex formula in which this STR is located, a link between this STR and instances of 
cognition deficit (a property that is severely compromised in NCD), its predominant expression in the human 
brain, and proximity to the + 1 TSS.
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Materials and methods
Subjects. Seven hundred fifty unrelated Iranian male subjects (age ≥ 60 years), consisting of late-onset NCD 
patients (n = 268) and controls (n = 482) were recruited from the provinces of Qazvin and Rasht. All patients 
were included based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for NCD. In each 
participant, the Persian version of the Abbreviated Mental Test Score (AMTS) was implemented (inclusion cri-
teria: AMTS < 7), medical history was taken, complemented by CT-scans in a number of instances (Suppl. 1). 
The control group was selected based on AMTS of ≥ 8, and history in all subjects, and normal CT-scan where 
possible. The AMTS is currently one of the most accurate primary screening instruments to increase the prob-
ability of  NCD20. The Persian version of the AMTS is a valid cognitive assessment tool for older Iranian adults 
and can be reliably used for NCD screening in Iran, with an over 90%  sensitivity19. The cases and controls were 
matched based on age and residential district. Informed consent was obtained from the subjects (informed 
consent was obtained from the guardians of all the subjects where necessary) and their identities remained 
confidential throughout the study. This research was approved by the Ethics Committee of the University of 
Social Welfare and Rehabilitation Sciences, Tehran, Iran, and was consistent with the principles outlined in an 
internationally recognized standard for the ethical con duct of human research.
Statistical analysis. The chi-squared test was used to compare the distribution of each allele between the 
control and NCD groups. The Mid-P exact test was used for the alleles detected at the extreme ends of the allele 
distribution curve, which were detected in the NCD patients, and not in the controls in this study and two previ-
ous studies of SCZ and  BPD8,9. Levene’s test was used to assess the equality of variances of allelic distribution for 
the two groups.
Allele/genotype analysis of the ZMYM3 gene GA‑STR complex. Genomic DNA was obtained from 
peripheral blood using a standard precipitation method, and PCR was carried out as previously  described8. 
Briefly, PCRs were performed in a thermocycler (peqSTAR) under the following conditions: 94 °C for 4 min, 
followed by 40 cycles including denaturing at 94 °C for 30 s, annealing for 30 s at 63 °C, and extension at 72 °C 
for 30 s. A final extension was conducted at 72 °C for 5 min. All samples were sequenced for the ZMYM3 GA-
complex using an ABI PRISM 377 DNA sequencer.
Results
Variation status of the ZMYM3 GA‑STR complex in the human subjects studied. The complex 
in which the exceptionally long GA-STR (32-repeat) is located consists of four consecutive GA-STRs with the 
8-4-6-32 formula in  human8. The 8-4-6 formula was found to be monomorphic across the 750 human subjects 
studied. The exceptionally long GA-STR, however, was polymorphic in the human subjects studied. The 8-4-6-
32 formula was human-specific when screened in 31 species encompassing various orders, including Primates, 
Rodents, Laurasiatheria, Scandentia, and Afrotheria (Table 1).
Alteration of the overall allele/genotype architecture at the exceptionally long GA‑STR in 
late‑onset NCD patients vs. controls. The overall distribution of the alleles was compared between the 
NCD cases and controls, which revealed inequality of the population variances between the two groups [F (1, 
50) = 12.283; p = 0.001] (Fig. 1).
Allele range of the ZMYM3 GA‑repeat in the late‑onset NCD patients and controls. The allele 
range of the GA-repeat was between 18 and 41-repeats across the control subjects, and 17 and 43-repeats in the 
late-onset NCD patients (Fig. 1, Table 2).
Disease‑only alleles across the ZMYM3 exceptionally long GA‑STR in late‑onset NCD 
patients. Alleles were detected at 17, 20, 42, and 43-repeats in seven NCD patients (2.61% of the NCD cases) 
Figure 1.  Allele range of the ZMYM3 GA-repeat in the human subjects studied (cases and controls included).
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that were not detected in the control individuals (Mid-P exact = 0.0003) (Fig. 2). On the other hand, all alleles 
that were detected in the controls were also detected in the NCD patients. The 17-repeat is the shortest allele 
detected in our human samples to date. The longest allele detected in human to date is at 45-repeats, detected 
in a case of  SCZ8.
Clinical characteristics of the patients harboring disease‑only alleles. The seven patients harbor-
ing disease-only alleles (Table 3) revealed extensive abnormalities in the available CT-scan records (Fig. 3). The 
observed lesions included extensive hypodense areas, calcifications, cortical atrophy, and ventricular enlarge-
ment. In patients, 2, 3, and 4, bilateral periventricular hypodense areas were detected, which indicated possible 
chronic microvascular changes and vascular dementia. The remaining four patients may be having AD based 
Table 2.  Allele/genotype distribution of the ZMYM3 exceptionally long STR in NCD patients and controls. 
NCD neurocognitive disorder, CONT control. **p < 0.01, *p < 0.05.
Repeat size NCD CONT Chi square P-value
17 4 0 7.233** 0.00715755
18 0 7 3.929* 0.04746016
19 2 5 0.158 0.69100458
20 1 0 1.801 0.17959165
21 1 2 0.008 0.92873007
22 1 3 0.202 0.65311132
23 6 10 0.022 0.8820871
24 4 14 1.466 0.22597787
25 15 19 0.374 0.54083196
26 26 34 0.901 0.34251372
27 20 54 2.71 0.09972099
28 38 67 0.011 0.91647033
29 28 47 0.093 0.76039737
30 27 49 0.002 0.96432941
31 24 39 0.167 0.68279188
32 16 47 3.2 0.07363827
33 11 31 1.764 0.18412637
34 9 21 0.447 0.50376306
35 14 12 3.848* 0.04980535
36 7 7 1.264 0.2608953
37 5 6 0.459 0.4980917
39 3 3 0.536 0.4640952
40 2 2 0.356 0.55073617
41 2 3 0.04 0.84148058
42 1 0 1.801 0.17959165
43 1 0 1.801 0.17959165
Total 268 482
Figure 2.  Electropherogarm of the ZMYM3 GA-repeat extreme alleles in the NCD patients.
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on the gradual deterioration of cognition in clinical examination and extensive temporal and cortical atrophy. 
CT-scans of a number of control individuals are also included for comparison (Fig. 4).
Discussion
The ZMYM3 GA-STR complex is human-specific in formula, the exceptionally long STR within this complex 
reaches maximum length in human, and the transcript encompassing this STR complex is specifically expressed 
in the brain (Table 1). ZMYM3 was previously reported among the top three regulators of AD  progression15. 
This gene may also link to other major disorders that are associated with major cognition impairment in human, 
such as SCZ, BPD, and intellectual  disability8,9,17,18. The above findings raise the possibility that ZMYM3 may be 
a master gene in the evolution of human cognition.
Table 3.  NCD patients harboring alleles at the extreme ends of the ZMYM3 exceptionally long GA-STR*. 
*Those alleles were not detected in our NCD cohort and two cohorts previously studied, including 
schizophrenia and bipolar disorder. **Abbreviated mental test score.
Patient no. Age STR repeat AMTS**
1 93 17 5
2 64 17 4
3 65 17 1
4 65 17 5
5 83 20 5
6 80 42 6
7 78 43 5
Figure 3.  CT-scan of the patients with the extreme alleles. (A) 17-repeat, (B) 17-repeat, (C) 42-repeat, (D) 
43-repeat. Extensive hypodense areas and calcification were detected in various brain sections.
Figure 4.  CT-scan of a number of control individuals.
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We investigated the ZMYM3 GA-STR complex in late-onset NCD as a clinical entity, without differentiating 
the subtypes of NCD. The advantage of this novel approach was to eliminate the often-ambiguous diagnoses 
made for the NCD subtypes, which frequently co-occur and overlap in respect of the clinical and pathophysi-
ological  manifestations9,21–25.
We found a significant skewing of the genetic architecture at the exceptionally long STR in the NCD patients 
vs. controls. Moreover, in seven NCD patients, we detected alleles that were not detected in the controls. A num-
ber of the disease-only alleles overlapped with alleles detected previously by our group in SCZ and  BPD9. The 17 
and 43-repeat alleles overlapped in NCD, SCZ and BPD, whereas, the 20-repeat allele overlapped in NCD and 
SCZ. It is possible that these alleles coincide with the overlapping cognition impairment component across the 
studied disorders. In line with the above findings, several other genes of overlapping nature have been reported 
by other groups across late-onset NCD and psychiatric  disorders26–28. The 42-repeat allele detected in the NCD 
patients was not detected in any human subjects studied to date.
Although the disease-only alleles detected by our group are at frequencies of < 0.02 in late-onset NCD, and 
encompass 2.61% of the patients, it is conceivable that fractional numbers of the remaining majority harbor 
alleles at unknown STR loci yet to be identified in the future studies. It is often claimed that genes affecting health 
in older age are beyond the reach of natural selection. However, findings on the APOE alleles and several other 
NCD susceptibility loci indicate that natural selection indeed happens in such  alleles29,30.
The reason we chose only male subjects is that ZMYM3 is X-linked, and therefore, it is expected that there are 
significant phenotypic differences as a result of gender. A future study is warranted to explore the significance of 
this STR in female subjects. Expansion of certain STR classes, especially trinucleotide repeats, can cause a range 
of neurological disorders, including Huntington disease, various ataxias, motor neuron disease, frontotemporal 
dementia, and fragile X  syndrome31. It remains to be clarified how the ZMYM3 GA-STR complex functions in 
the human brain. From what we know so far, GA-STRs of the range observed in the ZMYM3 complex can dra-
matically alter gene  expression32,33. ZMYM3 is among the top three master regulators causally responsible for 
regulating the transcriptional signature of AD  progression15. While GWAS approaches employ single nucleotide 
polymorphisms rather than STRs, and therefore can fail to detect instances of association with STRs, they have 
linked ZMYM3 to a number of neurological disorders of major cognitive impairment, including prion disease 
and multiple  sclerosis34,35.
Considering that the ZMYM3 GA-complex contains three of the longest GA-STRs identified in a human 
protein-coding gene 5′ UTR, this GA-rich region may also function as a X chromosome dosage compensation 
mechanism as described in model organisms such as Drosophila36. In human, the GAGA-binding c-Krox/Th/
POK protein specifically binds to (GA)837, and can modulate chromatin remodeling and gene expression activity. 
Of note, (GA)8 is one of the human-specific length STRs across the ZMYM3 STR complex.
Conclusion
In conclusion, the ZMYM3 GA-STR is a prime example in which alleles at the extreme short and long ends of 
exceptionally long STRs may be associated with a spectrum of major human disorders in which cognition impair-
ment is the predominant phenotype. Independent studies of various neurocognitive disorders are warranted to 
confirm the significance of our findings.
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